文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

医院获得性血流感染危重患者放弃维持生命治疗的实践差异:EUROBACT-2国际队列的二次分析

Variability in forgoing life-sustaining treatment practices in critically Ill patients with hospital-acquired bloodstream infections: a secondary analysis of the EUROBACT-2 international cohort.
PubMed 文献 · Crit Care · 2024-08-31
一句话结论EUROBACT-2二次分析显示,在考虑中心效应后,仅医疗支出(OR 1.79)与年龄(OR 1.02)与放弃维持生命治疗决策独立相关,非洲国家无此类决策报告。

本研究为EUROBACT-2研究(2019年6月至2021年1月,全球265个中心)的二次分析,纳入1589例非COVID-19医院获得性血流感染患者,评估死亡前是否作出放弃维持生命治疗决策。519例(32.7%)死亡,其中191例(36.8%)死亡前有放弃维持生命治疗决策。地理差异显著:非洲国家无放弃维持生命治疗决策报告,中东少于西欧、澳大利亚和亚洲。考虑中心效应后,仅医疗支出(OR 1.79,95%CI 1.45-2.21,p<0.01)和年龄(OR 1.02,95%CI 1.002-1.05,p=0.03)与放弃维持生命治疗决策显著相关,其他患者和病原体因素均不显著。作者认为经济和区域差异显著影响ICU终末期决策,全球政策应考虑这些差异以确保公平的终末期照护。

要点

  • 1589例非COVID-19医院获得性血流感染患者中519例(32.7%)死亡,其中191例(36.8%)死亡前有放弃维持生命治疗决策。
  • 地理差异显著:非洲国家无放弃维持生命治疗决策报告,中东少于西欧、澳大利亚和亚洲。
  • 考虑中心效应后,医疗支出与放弃维持生命治疗决策相关(OR 1.79,95%CI 1.45-2.21,p<0.01)。
  • 年龄与放弃维持生命治疗决策相关(OR 1.02,95%CI 1.002-1.05,p=0.03)。
  • 其他患者和病原体因素与放弃维持生命治疗决策无显著关联。

适用人群与场景

  • EUROBACT-2研究中非COVID-19、发生医院获得性血流感染且在院内或HABSI后28天内死亡的患者。

研究设计与关键结果

  • 研究类型:EUROBACT-2国际队列研究的二次分析;时间2019年6月至2021年1月;全球265个中心。
  • 人群:1589例非COVID-19医院获得性血流感染患者;519例(32.7%)死亡,其中191例(36.8%)死亡前有放弃维持生命治疗决策。
  • 地理差异:非洲国家无放弃维持生命治疗决策报告;中东少于西欧、澳大利亚和亚洲。
  • 单因素混合逻辑回归(随机中心效应):医疗支出OR 1.79(95%CI 1.45-2.21,p<0.01)、年龄OR 1.02(95%CI 1.002-1.05,p=0.03)与放弃维持生命治疗决策显著相关;其他患者和病原体因素不显著。

证据类型、等级与局限

  • 证据类型:国际多中心队列研究的二次分析;采用单因素混合逻辑回归模型(随机中心效应)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为经济和区域差异显著影响ICU终末期决策,全球政策应考虑这些差异以确保公平的终末期照护实践。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The decision to forgo life-sustaining treatment in intensive care units (ICUs) is influenced by ethical, cultural, and medical factors. This study focuses on a population of patients with hospital-acquired bloodstream infections (HABSI) to investigate the association between patient, pathogen, center and country-level factors and these decisions.

METHODS: We analyzed data from the EUROBACT-2 study (June 2019-January 2021) from 265 centers worldwide, focusing on non-COVID-19 patients who died in the hospital or within 28 days after HABSI. We assessed whether death was preceded by a decision to forgo life-sustaining treatment, examining country, center, patient, and pathogen variables. To assess the association of each potentially important variable with the decision to forgo life-sustaining treatment, univariable mixed logistic regression models with a random center effect were performed.

RESULTS: Among 1589 non-COVID-19 patients, 519 (32.7%) died, with 191 (36.8%) following a decision to forgo life-sustaining treatment. Significant geographical differences were observed, with no reported decisions to forgo life-sustaining treatment in African countries and fewer in the Middle East compared to Western Europe, Australia, and Asia. Once a center effect was considered, only health expenditure (Odds ratio 1.79, 95%CI: 1.45-2.21, p < 0.01) and age (Odds ratio 1.02, 95%CI: 1.002-1.05, p = 0.03) were significantly associated with decisions to forgo life-sustaining treatment, while other patient and pathogen factors were not.

CONCLUSION: Economic and regional disparities significantly impact end-of-life decision-making in ICUs. Global policies should consider these disparities to ensure equitable end-of-life care practices.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Wozniak H, Tabah A, De Waele JJ, et al. Variability in forgoing life-sustaining treatment practices in critically Ill patients with hospital-acquired bloodstream infections: a secondary analysis of the EUROBACT-2 international cohort. Crit Care. 2024. PMID: 39217394. doi:10.1186/s13054-024-05072-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。